Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,accountsPayable,otherCurrentLiab,longTermDebt,deferredLongTermLiab,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,netBorrowings,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,priceHint,exchange,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,exchangeDataDelayedBy,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,HEPA,110806217.0,76225200,3498655,,-6057306,,-6057306,2532808,0,-6031463,-6031463,,-2054,,,,0,0,6031463,0,-25843,,-6057306,-6062593,3190000.0,226022287.0,6182316.0,115867141.0,123756872.0,7623.0,-110162769.0,3014484.0,1870924.0,285098.0,115449085.0,2867449.0,176585.0,666119.0,117744731.0,1662444.0,,,,-1902277.0,-82105.0,82153600.0,-389468.0,82153600.0,74722247.0,-7349248.0,18143.0,981660.0,-82105.0,,114877282.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1.65,1630526403,0.03999996,1.64,1.65,1.59,629711,2.4844697,1.59 - 1.65,1.61,0.0,0.0,40,30,finmb_244424098,NasdaqCM,"Hepion Pharmaceuticals, Inc.",USD,1849929,760685,0.28999996,0.21323526,1.36 - 3.85,-2.1999998,-0.57142854,1.36,3.85,1559520000,4,NCM,-10.333,-1.42,-0.36,-4.583333,4.201,1.5188571,0.13114285,0.08634312,1.8142029,-0.16420293,-0.09050968,125771576,-1.1619718,0.3927636,15,America/New_York,EDT,-14400000,False,False,0,"Hepion Pharmaceuticals, Inc.",us_market,PRE,1.12,,,3.85,1.36,1.5189,1.8142,1.85M,760.68k,76.23M,,67.62M,0.14%,23.72%,1.32M,0.84,1.73%,1.73%,1.84M,,,,,,0.00%,"Jun 02, 2019",,1:70,"Jun 02, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-18.70%,-32.54%,,,,,-21.94M,-22.2M,-10.3330,,115.45M,1.51,688.11k,0.58,41.06,4.20,-18.84M,-10.38M,Value,08837,Healthcare,13,"Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.",Edison,732 902 4000,NJ,1609372800,United States,http://www.hepionpharma.com,86400,399 Thornall Street,732 902 4100,Biotechnology,First Floor
t-1,HEPA,33747339.0,76225200,2627096,,-4958642,,-4955699,2325634,0,-4952730,-4952730,,-15070,,,,-2943,0,4952730,0,-5912,,-4955699,-4955699,3190000.0,142910523.0,8124862.0,38808263.0,48645253.0,3203.0,-104105463.0,2990695.0,1870924.0,285098.0,40726838.0,4661827.0,,664932.0,42634299.0,3722429.0,37160.0,176585.0,,701323.0,-76546.0,31617458.0,-1261282.0,31617458.0,27015504.0,-4525408.0,13582.0,976668.0,-76546.0,,37972472.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1.65,1630526403,0.03999996,1.64,1.65,1.59,629711,2.4844697,1.59 - 1.65,1.61,0.0,0.0,40,30,finmb_244424098,NasdaqCM,"Hepion Pharmaceuticals, Inc.",USD,1849929,760685,0.28999996,0.21323526,1.36 - 3.85,-2.1999998,-0.57142854,1.36,3.85,1559520000,4,NCM,-10.333,-1.42,-0.36,-4.583333,4.201,1.5188571,0.13114285,0.08634312,1.8142029,-0.16420293,-0.09050968,125771576,-1.1619718,0.3927636,15,America/New_York,EDT,-14400000,False,False,0,"Hepion Pharmaceuticals, Inc.",us_market,PRE,1.12,,,3.85,1.36,1.5189,1.8142,1.85M,760.68k,76.23M,,67.62M,0.14%,23.72%,1.32M,0.84,1.73%,1.73%,1.84M,,,,,,0.00%,"Jun 02, 2019",,1:70,"Jun 02, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-18.70%,-32.54%,,,,,-21.94M,-22.2M,-10.3330,,115.45M,1.51,688.11k,0.58,41.06,4.20,-18.84M,-10.38M,Value,08837,Healthcare,13,"Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.",Edison,732 902 4000,NJ,1609372800,United States,http://www.hepionpharma.com,86400,399 Thornall Street,732 902 4100,Biotechnology,First Floor
t-2,HEPA,9289754.0,76225200,3782505,,-6293586,,-6231542,2448489,0,-6230994,-6230994,,-16159,,,,-62044,0,6230994,0,-62592,,-6231542,-6236829,,110309541.0,7490882.0,11160678.0,20363688.0,901.0,-99149764.0,2999853.0,1870924.0,3480604.0,13711334.0,3955974.0,,659669.0,14352491.0,1296545.0,522075.0,176585.0,3190000.0,1385068.0,-1.0,31617458.0,-17893.0,31617458.0,-3850479.0,-3850478.0,7204.0,1006685.0,-1.0,,10396517.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1.65,1630526403,0.03999996,1.64,1.65,1.59,629711,2.4844697,1.59 - 1.65,1.61,0.0,0.0,40,30,finmb_244424098,NasdaqCM,"Hepion Pharmaceuticals, Inc.",USD,1849929,760685,0.28999996,0.21323526,1.36 - 3.85,-2.1999998,-0.57142854,1.36,3.85,1559520000,4,NCM,-10.333,-1.42,-0.36,-4.583333,4.201,1.5188571,0.13114285,0.08634312,1.8142029,-0.16420293,-0.09050968,125771576,-1.1619718,0.3927636,15,America/New_York,EDT,-14400000,False,False,0,"Hepion Pharmaceuticals, Inc.",us_market,PRE,1.12,,,3.85,1.36,1.5189,1.8142,1.85M,760.68k,76.23M,,67.62M,0.14%,23.72%,1.32M,0.84,1.73%,1.73%,1.84M,,,,,,0.00%,"Jun 02, 2019",,1:70,"Jun 02, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-18.70%,-32.54%,,,,,-21.94M,-22.2M,-10.3330,,115.45M,1.51,688.11k,0.58,41.06,4.20,-18.84M,-10.38M,Value,08837,Healthcare,13,"Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.",Edison,732 902 4000,NJ,1609372800,United States,http://www.hepionpharma.com,86400,399 Thornall Street,732 902 4100,Biotechnology,First Floor
t-3,HEPA,14704313.0,76225200,2950340,,-4844509,,-4940080,1825074,0,-4775414,-4775414,,-16159,,,,95571,0,4775414,0,-69095,,-4940080,-4940080,,108923663.0,5791554.0,16575237.0,24083632.0,901.0,-92349327.0,2593575.0,1870924.0,3318289.0,17561813.0,2603136.0,,725480.0,18168939.0,972362.0,89389.0,176585.0,3190000.0,675136.0,-11436.0,4636934.0,652257.0,4460349.0,1514144.0,-3111354.0,7202.0,494131.0,-11436.0,176585.0,15565803.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,1.65,1630526403,0.03999996,1.64,1.65,1.59,629711,2.4844697,1.59 - 1.65,1.61,0.0,0.0,40,30,finmb_244424098,NasdaqCM,"Hepion Pharmaceuticals, Inc.",USD,1849929,760685,0.28999996,0.21323526,1.36 - 3.85,-2.1999998,-0.57142854,1.36,3.85,1559520000,4,NCM,-10.333,-1.42,-0.36,-4.583333,4.201,1.5188571,0.13114285,0.08634312,1.8142029,-0.16420293,-0.09050968,125771576,-1.1619718,0.3927636,15,America/New_York,EDT,-14400000,False,False,0,"Hepion Pharmaceuticals, Inc.",us_market,PRE,1.12,,,3.85,1.36,1.5189,1.8142,1.85M,760.68k,76.23M,,67.62M,0.14%,23.72%,1.32M,0.84,1.73%,1.73%,1.84M,,,,,,0.00%,"Jun 02, 2019",,1:70,"Jun 02, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-18.70%,-32.54%,,,,,-21.94M,-22.2M,-10.3330,,115.45M,1.51,688.11k,0.58,41.06,4.20,-18.84M,-10.38M,Value,08837,Healthcare,13,"Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.",Edison,732 902 4000,NJ,1609372800,United States,http://www.hepionpharma.com,86400,399 Thornall Street,732 902 4100,Biotechnology,First Floor
